The company presented new data from the Phase 2b VIRAGE trial evaluating VCN-01 in combination with gemcitabine/nab-paclitaxel (GnP) for metastatic pancreatic cancer. Patients treated with VCN-01 plus GnP demonstrated improved overall survival (OS) and progression-free survival (PFS) compared to GnP alone. The data suggests an immune-mediated mechanism of action for VCN-01, characterized by later-emerging and more durable responses. Patients receiving a second administration of VCN-01 showed a greater benefit in OS and PFS. The survival benefit was maintained across subgroups, including patients with liver metastases, even after adjusting for baseline imbalances.